NeuroFLiPP: Parametric PET of Neuroinflammation in Fatty Liver Disease
Recruiting
Early Phase 1
Interventional Study
Positron Emission Tomography
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Early Phase 1
- Study type
- Interventional
- Purpose
- Other
- Participants needed
- 12 (estimated)
- Sponsor
- University of California, Davis · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Alzheimer's Disease and related dementias (ADRD) affect about 6 million people in the U.S. and are the fifth leading cause of death for adults over 65. Recent research is investigating how chronic liver diseases like Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which affects one-third of the U.S. population, might influence ADRD through the liver-brain axis. MASLD shares risk …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Participants \>=18 years age
* Participants who have or have planned a liver biopsy as:
* standard of care for fatty liver disease with risk factors for metabolic dysfunction-associated steatohepatitis (MASH), or
* as part of another Clinical Trials study for MASH, or
*…
Contacts